A Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetic / Pharmacodynamic Effects of a Targeted Exposure of Intravenous Repinotan in Patients With Acute Ischemic Stroke

The purpose of this trial is to evaluate Repinotan HCl in patients with acute ischemic stroke. At study entry patients will be randomized to Repinotan HCl or placebo in a 1:1 ratio. The total treatment period wil be 72 hours.

Start Date01 Dec 2000

Sponsor / Collaborator

Bayer AG

100 Clinical Results associated with Repinotan Hydrochloride

100 Translational Medicine associated with Repinotan Hydrochloride

100 Patents (Medical) associated with Repinotan Hydrochloride

Literatures (Medical) associated with Repinotan Hydrochloride

01 Mar 2025·PHARMACEUTICAL CHEMISTRY JOURNAL

Prediction of the Drug’s Clearance Correlation Between Humans and Rats

Author: Shayanfar, Ali ; Navaei, Kiana Shabani

Animal species, i.e. rats, are used to evaluate a drugs biol. activity and pharmacokinetics, such as clearance.This study aims to develop a predictive method to evaluate the relationship between the clearance of drugs in rats and humans.Adataset of 395 drugs composed of human and rat clearance data was applied in this study.The drugs, according to the clearance differences, were divided into two groups on the basis of the correlation between humans and rats.Structural parameters were used to develop a model to estimate the class of each drug by binary logistic regression.The results showed that the developed models are a useful way to show which drug have an acceptable correlation between human and rat clearance by using structural features.They can be used to determine the group of drugs with an accuracy of 74%.According to the validation results, the developed method has an acceptable accuracy for checking the relationship between the clearance of drugs in humans and rats.This modeling can be used to exclude the drugs from experiments in rats which reveal a considerable difference between the clearance of humans and that of rats.

20 Jan 2023·ACS Catalysis

Asymmetric Catalytic Conjugate Addition of Cyanide to Chromones and β-Substituted Cyclohexenones

Author: Ye, Dong ; Liu, Xiaohua ; Chen, Qiyou ; Zhou, Yuqiao ; Mo, Yuhao ; Li, Jinzhao ; Feng, Xiaoming ; Dong, Shunxi

A highly enantioselective conjugate cyanation of cyclic α,β-unsaturated ketones was achieved with dual catalysis of chiral Lewis acids and achiral organic bases.A variety of chromones and β-substituted cyclohexenones were transformed into the desired β-cyano ketone derivatives such as I [R¹ = H, 7-F, 7-OAc, etc.; R² = H, 6-F, 6-Br, etc.] in good yields with high enantioselectivities under mild conditions.The metal salts Ce(OTf)₃ and Ba(OTf)₂ in combination with chiral N,N'-dioxides facilitated the reaction well, revealing a close connection between the outcome of the reaction and the Lewis acidity with metal ion radii.The application of the methods was highlighted by the facile synthesis of the bioactive compounds repinotan and sarizotan.

100 Deals associated with Repinotan Hydrochloride

External Link

KEGG	Wiki	ATC	Drug Bank
-	Repinotan Hydrochloride	-	DB06506

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Acute Ischemic Stroke	Phase 2	United States	Bayer AG	01 Dec 2000
Acute Ischemic Stroke	Phase 2	Australia	Bayer AG	01 Dec 2000
Acute Ischemic Stroke	Phase 2	Austria	Bayer AG	01 Dec 2000
Acute Ischemic Stroke	Phase 2	Belgium	Bayer AG	01 Dec 2000
Acute Ischemic Stroke	Phase 2	Canada	Bayer AG	01 Dec 2000
Acute Ischemic Stroke	Phase 2	Finland	Bayer AG	01 Dec 2000
Acute Ischemic Stroke	Phase 2	France	Bayer AG	01 Dec 2000
Acute Ischemic Stroke	Phase 2	Germany	Bayer AG	01 Dec 2000
Acute Ischemic Stroke	Phase 2	Hungary	Bayer AG	01 Dec 2000
Acute Ischemic Stroke	Phase 2	Israel	Bayer AG	01 Dec 2000

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis